|
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatocellular adenomas (HCA) are benign liver tumors mainly related to oral contraception and classified into 4 molecular subgroups: inflammatory (IHCA), HNF1A-inactivated (H-HCA), β-catenin-activated (bHCA) or unclassified (UHCA).
|
23046672 |
2013 |
|
Hepatocellular Adenoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Hepatocellular adenomas (HCAs) are heterogeneous group of benign tumors; three pathomolecular subtypes have been identified so far: hepatocyte nuclear factor 1 α-inactivated HCA (H-HCA) (35-40%), inflammatory HCA (I-HCA) (>50%), β-catenin activated HCA (10%).
|
25260568 |
2015 |
|
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
HCA were classified as inflammatory (n = 6), steatotic (n = 4), or β-catenin activated (n = 1) subtypes.
|
30052636 |
2018 |
|
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
β-catenin activating HCA has increased activity of the Wnt/β-catenin pathway and is associated with possible malignant transformation.
|
25195525 |
2015 |
|
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CTNNB1 mutated HCA in exon 3 and sonic hedgehog HCA have been linked with a high risk of malignant transformation and bleeding respectively.
|
28733222 |
2017 |
|
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
All 36 sequenced HCAs showed HNF1α mutations (72% missense, 28% synonymous), 2 hotspot polymorphisms of HNF1α (I27L: rs1169288 and S487N: rs2464196) were seen in 17 (47%) and 10 (27.8%) cases, respectively, and a novel single nucleotide polymorphism site (rs1169304) in intron 9 of HNF1α was detected in 32 (88%) cases, but no β-catenin or gp130 gene mutation was detected, and no nuclear β-catenin staining was detected by immunohistochemistry.
|
26608415 |
2015 |
|
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
All six hepatocellular adenomas with malignancy were β-catenin activated; β-catenin activation could serve as a biomarker for malignant progression.
|
31698521 |
2019 |
|
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysis of 96 hepatocellular adenomas performed by a French collaborative network showed that they can be divided into four broad subgroups: the first one is defined by the presence of mutations in TCF1 gene inactivating the hepatocyte nuclear factor 1 (HNF1 alpha); the second by the presence of beta-catenin activating mutations; the category without mutations of HNF1 alpha or beta-catenin is further divided into 2 subgroups depending on the presence or absence of inflammation.
|
17569132 |
2007 |
|
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Atypical hepatocellular adenoma-like neoplasms with β-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas.
|
23084586 |
2013 |
|
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Finally, in a few MODY3 patients with HNF1A germline mutation leading to amino acid substitutions outside the POU-H domain, we identified a different subtype of HCA either with a gp130 and/or CTNNB1 activating mutation.
|
20393147 |
2010 |
|
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Finally, integrative analysis of HCAs transformed to hepatocellular carcinoma revealed β-catenin mutation as an early alteration and TERT promoter mutations as associated with the last step of the adenoma-carcinoma transition.
|
24735922 |
2014 |
|
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Focal β-catenin mutation identified on formalin-fixed and paraffin-embedded inflammatory hepatocellular adenomas.
|
28618047 |
2017 |
|
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Gene expression and mutation assessment provide clues of genetic and epigenetic mechanisms in liver tumors of oxazepam-exposed mice.
|
21147764 |
2011 |
|
Hepatocellular Adenoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Genotype-phenotype classification of the pigmented tumors showed different subtypes: HNF1α inactivated (48%), β-catenin activated (26%), inflammatory (15%), concurrently β-catenin activated and inflammatory in 1 hepatocellular adenoma, concurrently HNF-1α inactivated and β-catenin activated in 1 hepatocellular adenoma, and unclassified in 1 hepatocellular carcinoma.
|
26205181 |
2015 |
|
Hepatocellular Adenoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HAs presented as a heterogeneous group, with loss of PTEN observed in the inflammatory and HNF1A-mutated subtype and relatively intact PTEN expression in HA with nuclear β-catenin overexpression.
|
29687774 |
2017 |
|
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the hepatocellular adenoma-like portion of most cases of hepatocellular carcinoma arising in hepatocellular adenoma shows features typically seen in hepatocellular carcinoma such as focal morphological abnormalities, β-catenin activation, heat-shock protein 70 expression, and chromosomal gains.
|
24743216 |
2014 |
|
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the molecular and pathological classification of hepatocellular adenomas permits the identification of strong genotype-phenotype correlations and suggests that adenomas with beta-catenin activation have a higher risk of malignant transformation.
|
16496320 |
2006 |
|
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In HCA, CTNNB1 mutations predispose to transformation of HCA in HCC and TERT promoter mutations are required in most of the cases as a second hit for a full malignant transformation.
|
26336998 |
2016 |
|
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Liver fatty acid-binding protein, serum amyloid A, C-reactive protein, prostaglandin D2 synthetase, GS, and β-catenin can be used either on biopsy or surgical specimen to classify hepatocellular adenoma into hepatocyte nuclear factor (HNF-1α) inactivated (steatotic), inflammatory, with dysregulation of sonic hedgehog and prostaglandin pathways, β-catenin mutated, and unclassified.
|
28280721 |
2017 |
|
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Meanwhile, β-catenin mutated hepatocellular adenoma patients with malignant transformation were predominantly male (67%, p = 0.018) with single lesion (86%, p = 0.0009).
|
31570768 |
2019 |
|
Hepatocellular Adenoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our report may be the first to describe the beta-catenin abnormalities in childhood liver cell adenoma.
|
12203220 |
2002 |
|
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, while chronic administration of the model CAR activator NaPB results in both hepatocellular adenoma and carcinoma in the low spontaneous liver tumour incidence C57BL/10 J mouse strain, only 40% of the liver tumours evaluated in this study had β-catenin mutations.
|
31836555 |
2020 |
|
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymerase chain reaction (PCR) amplification and direct sequencing of all samples of HA and FNH displayed no mutations in exon 3 of the beta-catenin gene.
|
12297840 |
2002 |
|
Hepatocellular Adenoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Previously described associations were confirmed and in particular the significant association between beta-catenin-activated HCA and hepatocellular carcinomas (HCC) at diagnosis or during follow-up (P < 10(-5)).
|
17663417 |
2007 |
|
Hepatocellular Adenoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, inactivating mutations of hepatocyte nuclear factor-1alpha (HNF-1alpha) transcription factor gene or activating mutations of beta-catenin have been demonstrated in some liver adenomas, and a possible link between HNF-1alpha gene mutations and oral contraceptives has been suggested.
|
17535860 |
2007 |